Of 36 patients with KMT2A-rearranged or NPM1-mutated AML that were treated with the recommended phase-2 dose, the CR/CRh-rate was 25%, and 35% in the NPM1-mutated AML cohort, respectively [107]. The gene discussed is NPM1; the disease is acute myeloid leukemia.